Multi-criteria decision analysis (MCDA) can improve the healthcare decision-making process by considering an explicit set of criteria and their relative importance under a fully transparent process.

This study approximated the overall estimated value of two innovative drugs for chronic inflammatory skin diseases (atopic dermatitis and psoriasis) from a broad and systematic view, while incorporating local multi-disciplinary views to express a societal perspective.

This exercise allows us to better understand where the value of dupilumab and secukinimab lies for the different stakeholders, providing useful information that could help to make better decisions on the assessment, pricing and public reimbursement of these interventions.